Full Professor(heuristic)

Colorectal Cancer Treatments and Studies · Oncology

Compare more Oncology professors.

h-index77
i10-index260
Publications827
Citations26,856

Grants

5 total · 1 active

NIH #R50CA285499

Cultivating programmatic efforts to optimize the conduct and implementation of NCI-funded clinical trials

Active
Amount
$100K–$200K
Period
2024-09-182029-08-31
PIs
1

Awarded at VANDERBILT UNIVERSITY MEDICAL CENTER

NIH #P30CA068485

Gastrointestinal Cancer Research Program

Amount
<$100K
Period
1998-09-012025-08-31
PIs
1

Awarded at VANDERBILT UNIVERSITY MEDICAL CENTER

NIH #U10CA180858

UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)

Amount
$1M–$2M
Period
2014-04-152019-02-28
PIs
3

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →

All Grants

5 total · 1 active

NIH #R50CA285499

Cultivating programmatic efforts to optimize the conduct and implementation of NCI-funded clinical trials

Active
Amount
$100K–$200K
Period
2024-09-182029-08-31
PIs
1

Awarded at VANDERBILT UNIVERSITY MEDICAL CENTER

NIH #P30CA068485

Gastrointestinal Cancer Research Program

Amount
<$100K
Period
1998-09-012025-08-31
PIs
1

Awarded at VANDERBILT UNIVERSITY MEDICAL CENTER

NIH #U10CA180858

UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP)

Amount
$1M–$2M
Period
2014-04-152019-02-28
PIs
3

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #U10CA105409

U10 Full Member Application Affiliated with SWOG

Amount
$300K–$400K
Period
2004-07-262015-12-31
PIs
1

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

NIH #R21CA158676

Determinants of Efficacy to the Akt Inhibitor Perifosine in Colorectal Cancer

Amount
$200K–$300K
Period
2011-07-012013-06-30
PIs
1

Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR

Recent Public Signals

  1. New paper: Supplementary Figure S1 from Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal2026-06-17
  2. New NIH award: Cultivating programmatic efforts to optimize the conduct and implementation of NCI-funded clinical trials2024-09-18

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

Data Freshness

  • Publications as of 2026-07-09
  • Grants as of 2026-08-26

Data may not be current

Find elsewhere

ORCID: 0000-0003-2335-0612

Professor Insights

Career Trajectory